Respiratory News and Research

RSS

Study: Lorazepam drug not effective in treating pediatric status epilepticus

A National Institutes of Health-sponsored study published in the Journal of the American Medical Association showed that lorazepam - a widely used but not yet Food and Drug Administration approved drug for children - is no more effective than an approved benzodiazepine, diazepam, for treating pediatric status epilepticus.

15 May 2014

Lung microbes offer protection against allergic asthma

Whether or not people develop asthma may be determined in the first few weeks after birth according to a study of mice funded by the Swiss National Science Foundation (SNSF).

15 May 2014

WHO's annual statistics report shows global life expectancy continues to increase

People everywhere are living longer, according to the "World Health Statistics 2014" published today by WHO. Based on global averages, a girl who was born in 2012 can expect to live to around 73 years, and a boy to the age of 68.

15 May 2014

Depression is the leading cause of illness in adolescents, shows WHO's report

WHO's "Health for the world's adolescents" report reveals that depression is the predominant cause of illness and disability for both boys and girls aged 10 to 19 years.

15 May 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2014.

14 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

12 May 2014

New implantable cuff with 24 electrodes helps reduce high blood pressure

Freiburg researchers develop new method for lowering high blood pressure without side effects. High blood pressure is the greatest health risk worldwide behind smoking and alcohol consumption.

12 May 2014

FLUIDDA's breakthrough imaging technology helps optimize COPD treatment

FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD).

9 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Triple therapy shows promise for severe PAH

Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.

7 May 2014

USPTO issues three new patents to Discovery Laboratories

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent and Notices of Allowance for patents covering critical aspects of its KL4 surfactant and drug delivery technology platform.

7 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

While many parents-to-be are aware that the health of their baby starts before they've actually arrived into the world, recent research reveals that "harm" (i.e., tobacco smoke, dirty air, poor nutrition, even preeclampsia) may not present itself disease-wise until well into adulthood or when a second harmful "hit" triggers the individual's susceptibility.

6 May 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

Respiratory News and Research

Study: Lorazepam drug not effective in treating pediatric status epilepticus

Lung microbes offer protection against allergic asthma

WHO's annual statistics report shows global life expectancy continues to increase

Depression is the leading cause of illness in adolescents, shows WHO's report

Aradigm reports total revenue of $6.6 million for Q1 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

New implantable cuff with 24 electrodes helps reduce high blood pressure

FLUIDDA's breakthrough imaging technology helps optimize COPD treatment

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Triple therapy shows promise for severe PAH

USPTO issues three new patents to Discovery Laboratories

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Protein molecule seems to slow progression of deadly lung disease

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Teva's SYNRIBO for injection receives FDA approval for home administration

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News